Effects of testosterone replacement therapy on bone metabolism in male post-surgical hypogonadotropic hypogonadism: Focus on the role of androgen receptor CAG polymorphism

Journal of Endocrinological Investigation

Volumn 37, Issue 4, 2014, Pages 393-400

  Tirabassi, G ^a   Delli Muti, N ^a   Gioia, A ^a   Biagioli, A ^a   Lenzi, A ^b   Balercia, G ^a  

^a Azienda Ospedaliera Umberto I   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Androgen receptor; Bone; Hypogonadotropic hypogonadism; Hypopituitarism; Testosterone

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANDROGEN RECEPTOR; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PARATHYROID HORMONE; SOMATOMEDIN C; TESTOSTERONE;

ADULT; ANDROGEN THERAPY; ARTICLE; BONE DENSITY; BONE METABOLISM; CAG REPEAT; CLINICAL ARTICLE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; MALE; POSTOPERATIVE CARE; RETROSPECTIVE STUDY; BLOOD; BONE; DRUG EFFECTS; GENETICS; HORMONE SUBSTITUTION; HYPOGONADISM; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PITUITARY NEOPLASMS; POSTOPERATIVE COMPLICATION; TRINUCLEOTIDE REPEAT;

BONE AND BONES; BONE DENSITY; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; TESTOSTERONE; TRINUCLEOTIDE REPEATS;

EID: 84900552741     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0052-2     Document Type: Article

References (41)

1. Oury F (2012) A crosstalk between bone and gonads. Ann N Y Acad Sci 1260:1-7
2. Tirabassi G, Gioia A, Giovannini L et al (2013) Testosterone and cardiovascular risk. Intern Emerg Med 8(Suppl 1):S65-S69
3. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L (2011) Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 165:675-685
4. Snyder PJ, Peachey H, Hannoush P et al (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966-1972
5. Aversa A, Bruzziches R, Francomano D et al (2012) Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male 15:96-102
6. Carnevale V, Romagnoli E, Cipriani C et al (2010) Sex hormones and bone health in males. Arch Biochem Biophys 503:110-117
7. Clarke BL, Khosla S (2009) Androgens and bone. Steroids 74:296-305
8. Delli Muti N, Agarwal A, Buldreghini E, et al (2013) Have androgen receptor gene CAG and GGC repeat polymorphisms an effect on sperm motility in infertile men? Andrologia. doi:10.1111/and.12119. (Epub ahead of print)
9. Zitzmann M, Nieschlag E (2003) The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 26:76-83
10. Van Pottelbergh I, Lumbroso S, Goemaere S, Sultan C, Kaufman JM (2001) Lack of influence of the androgen receptor gene CAG-repeat polymorphism on sex steroid status and bone metabolism in elderly men. Clin Endocrinol (Oxf) 55:659-666
11. Olney RC (2003) Regulation of bone mass by growth hormone. Med Pediatr Oncol 41:228-234
12. Williams GR (2009) Actions of thyroid hormones in bone. Endokrynol Pol. 60:380-388
13. Arnaldi G, Mancini T, Tirabassi G, Trementino L, Boscaro M (2012) Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications. J Endocrinol Investig 35:434-448
14. Bhasin S, Cunningham GR, Hayes FJ et al (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536-2559
15. Saad F, Kamischke A, Yassin A et al (2007) More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate. Asian J Androl 9:291-297
16. Gabellieri E, Chiovato L, Lage M, Castro AI, Casanueva FF (2010) Testing growth hormone deficiency in adults. Front Horm Res 38:139-144
17. Persani L (2012) Clinical review: central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab 97:3068-3078
18. Grossman AB (2010) Clinical review: the diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 95:4855-4863
19. Rao SS, Budhwar N, Ashfaque A (2010) Osteoporosis in men. Am Fam Physician 82:503-508
20. Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R, Nieschlag E (2001) The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin Endocrinol (Oxf) 55:649-657
21. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E (2004) X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J Clin Endocrinol Metab 89:6208-6217
22. Guadalupe-Grau A, Rodríguez-González FG, Ponce-González JG et al (2010) Bone mass and the CAG and GGN androgen receptor polymorphisms in young men. PLoS ONE 5(7):e11529. doi:10.1371/journal. pone.0011529
23. Beilin J, Ball EM, Favaloro JM, Zajac JD (2000) Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol 25:85-96
24. Thomas JD, Monson JP (2009) Adult GH deficiency throughout lifetime. Eur J Endocrinol 161(Suppl 1):S97-S106
25. Tirabassi G, Papa R, Faloia E, Boscaro M, Arnaldi G (2011) Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo-Cushing state: a comparative study. Clin Endocrinol (Oxf) 75:666-672
26. Tirabassi G, Faloia E, Papa R, Furlani G, Boscaro M, Arnaldi G (2010) Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing's disease. J Clin Endocrinol Metab 95:1115-1122
27. Arnaldi G, Tirabassi G, Papa R et al (2009) Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing's disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. Eur J Endocrinol 160:891-898
28. Granata A, Tirabassi G, Pugni V et al (2013) Sexual dysfunctions in men affected by autoimmune Addison's disease before and after short-term gluco- and mineralocorticoid replacement therapy. J Sex Med 10:2036-2043
29. Andrioli M, Pecori Giraldi F, Cavagnini F (2006) Isolated corticotrophin deficiency. Pituitary 9:289-295
30. Løvås K, Gjesdal CG, Christensen M et al (2009) Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 160:993-1002
31. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA (1994) Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120:207-210
32. Nezzo M, De Visschere P, T'sjoen G, Weyers S, Villeirs G (2013) Role of imaging in the diagnosis and management of complete androgen insensitivity syndrome in adults. Case Rep Radiol 2013:158484. doi:10.1155/2013/158484
33. Bertelloni S, Baroncelli GI, Federico G, Cappa M, Lala R, Saggese G (1998) Altered bone mineral density in patients with complete androgen insensitivity syndrome. Horm Res 50:309-314
34. Sobel V, Schwartz B, Zhu YS, Cordero JJ, Imperato-McGinley J (2006) Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J Clin Endocrinol Metab 91:3017-3023
35. Diamond T, Campbell J, Bryant C, Lynch W (1998) The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83:1561-1566
36. Francomano D, Greco EA, Lenzi A, Aversa A (2013) CAG repeat testing of androgen receptor polymorphism: is this necessary for the best clinical management of hypogonadism? J Sex Med 10:2373-2381
37. Langdahl BL, Stenkjaer L, Carstens M, Tofteng CL, Eriksen EF (2003) A CAG repeat polymorphism in the androgen receptor gene is associated with reduced bone mass and increased risk of osteoporotic fractures. Calcif Tissue Int 73:237-243
38. Remes T, Väisänen SB, Mahonen A et al (2003) Aerobic exercise and bone mineral density in middle-aged finnish men: a controlled randomized trial with reference to androgen receptor, aromatase, and estrogen receptor alpha gene polymorphisms small star, filled. Bone 32:412-420
39. Välimäki VV, Piippo K, Välimäki S, Löyttyniemi E, Kontula K, Välimäki MJ (2005) The relation of the XbaI and PvuII polymorphisms of the estrogen receptor gene and the CAG repeat polymorphism of the androgen receptor gene to peak bone mass and bone turnover rate among young healthy men. Osteoporos Int 16:1633-1640
40. Stiger F, Brändström H, Gillberg P et al (2008) Association between repeat length of exon 1 CAG microsatellite in the androgen receptor and bone density in men is modulated by sex hormone levels. Calcif Tissue Int 82:427-435
41. Ferlin A, Schipilliti M, Vinanzi C et al (2011) Bone mass in subjects with Klinefelter syndrome: role of testosterone levels and androgen receptor gene CAG polymorphism. J Clin Endocrinol Metab 96:739-745